COVID-19 Clinical Trials
| Trials |
|---|
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized AdultsACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone and remdesivir in adult patients hospitalized with COVID-19 and requiring supplemental oxygen administered by low flow, high flow, or non-invasive mechanical ventilation. … ACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone and remdesivir in adult patients hospitalized with COVID-19 and requiring supplemental oxygen administered by low flow, high flow, or non-invasive mechanical ventilation. Hospitalized adults (>18 years) with symptoms suggestive of COVID-19 Illness of any duration and laboratory-confirmed SARS-CoV-2 infection within 14 days Requires low or high flow oxygen devices or non-invasive mechanical ventilation Has not received 5 or more doses of remdesivir as treatment for COVID-19 Has not receive 6mg or more of dexamethasone in one day, on more than one day in the past 7 days
NCT04280705 STU00212207 |
Positive Affect Regulation sKills (PARK)The Positive Affect Regulation sKills (PARK) Course is an online program that teaches positive emotion skills for individuals experiencing stress as a result of the COVID-19 outbreak, recommended/mandatory social distancing, and other related stressors (e.g., loss of income, shortages of daily essentials, etc.). The program consists of … The Positive Affect Regulation sKills (PARK) Course is an online program that teaches positive emotion skills for individuals experiencing stress as a result of the COVID-19 outbreak, recommended/mandatory social distancing, and other related stressors (e.g., loss of income, shortages of daily essentials, etc.). The program consists of 8 skills aimed at increasing the daily experience of positive emotion to help individuals cope with whatever stress they might be experiencing. The skills are presented over the course of 5 weeks and after learning each skill by reading through content on our platform, there is the opportunity to practice the skill on the platform as well. •At least 18 years of age •Speaks and reads English •Able to access the online platform through their phone, a public device (i.e., at the library) or at home •Lives in US STU00212262 |
NU COVID-19 MSK20H04: Examining COVID19 Course and Outcomes in Patients Previously Diagnosed with Chronic Lymphocytic Leukemia (CLL)This multicenter, retrospective cohort study will include patientstreated at national and international medical centers. Patients will be included if they have a prior diagnosis of CLL, havebeen diagnosed with COVID19, and received care at a participating medicalcenter. Primary Aim: To determine the 28-daymortality rate from the time of COVID … This multicenter, retrospective cohort study will include patientstreated at national and international medical centers. Patients will be included if they have a prior diagnosis of CLL, havebeen diagnosed with COVID19, and received care at a participating medicalcenter. Primary Aim: To determine the 28-daymortality rate from the time of COVID 19 diagnosis for CLL patients infectedwith SARS-CoV2 at MSKCC and other institutions. Secondary Aims: To describe baseline characteristics, prior and current CLL directed therapies, COVID19 clinical course and outcomes for CLL patients infected with SARS-CoV2. To examine relationships between CLL directed therapy and COVID19 disease course and outcomes. To examine current practices regarding management of CLL directed therapy in CLL patients infected with SARS-CoV2. |
Screening for Coronavirus Antibodies in Neighborhoods (SCAN)Inthe SCAN study, we are measuring how many people in the Chicagoland area haveantibodies to SARS-CoV-2 (the virus that causes COVID-19), how widespread theinfection has been in Chicago, and whether some neighborhoods had moreinfection than others. By taking part, you will help us find out how many … Inthe SCAN study, we are measuring how many people in the Chicagoland area haveantibodies to SARS-CoV-2 (the virus that causes COVID-19), how widespread theinfection has been in Chicago, and whether some neighborhoods had moreinfection than others. By taking part, you will help us find out how many peoplein specific areas have been exposed to SARS-CoV-2, and if these antibodiesprotect people against re-infection. |
COVID Prevention Trials RegistryAfteryou provide consent, you will be asked to complete a survey to collect some informationabout your health and risk of exposure to COVID. The study team may contact you to assess yourpotential eligibility for COVID prevention trials when they open. You may open the consent and registry survey in your … Afteryou provide consent, you will be asked to complete a survey to collect some informationabout your health and risk of exposure to COVID. The study team may contact you to assess yourpotential eligibility for COVID prevention trials when they open. You may open the consent and registry survey in your web browser by clickingthe link below: COVID PreventionTrials Registry Consent . If thelink above does not work, try copying the link below into your web browser: https://is.gd/NUVaccineStudy The NorthwesternCOVID Prevention Trials Registry is open to all adults who are interested inbeing contacted about upcoming COVID vaccine and other prevention studies. TheCOVID vaccine trials will enrollpersonswhoareatrisk of infection and COVID-19 disease. This· · · - - - Racial/ethnic groups such as African Americans, Latinx, and NativeAmericanpopulations. STU00213110 |
COVID-19 TestUS an initiative of RADx AcceleRATeD study (Rapid Assessment of Technology for SARS-CoV-2 Detection)We are studying the accuracy and usability of NEW point-of-care COVID-19 diagnostic tests compared to standard laboratory testing. You will be asked to come to our clinic for ONE visit to collect nasal swabs (less than one inch into each nostril) for new and standard tests. You … We are studying the accuracy and usability of NEW point-of-care COVID-19 diagnostic tests compared to standard laboratory testing. You will be asked to come to our clinic for ONE visit to collect nasal swabs (less than one inch into each nostril) for new and standard tests. You will also complete surveys through a web browser, App on mobile device, or telephone interview with research staff. These surveys take approximately 30 minutes and they collect information on prior COVID-19 testing, COVID-19 exposures, demographics, and brief medical history. |
A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults with COVID-19Patients with COVID-19 disease are at risk of blood clots, which may affect many parts of the body. It is recommended that patients hospitalized with COVID-19 disease be placed on a blood thinner called heparin to prevent clots. The purpose of this study is to determine if adding … Patients with COVID-19 disease are at risk of blood clots, which may affect many parts of the body. It is recommended that patients hospitalized with COVID-19 disease be placed on a blood thinner called heparin to prevent clots. The purpose of this study is to determine if adding a platelet inhibitor, a different type of blood thinner, will be even better at reducing the risk of blood clots. All of these blood thinner medications are already approved by the United States Food and Drug Administration (FDA) for preventing clots in different situations. We do not currently know the best combination of these drugs in people hospitalized with COVID-19. Participants in this study will receive an assigned study treatment that will last up to 14 days or until discharge from the hospital, whichever comes first. The study team will also contact participants about 90 days after hospital discharge and about 1 year after hospital discharge to check on the participant's health. Currently, participants will be randomly assigned to either blood thinner alone or blood thinner with platelet inhibitor. Participants may also optionally give blood samples at four different times during their hospital stay. The blood will be stored for future genetic research.
NCT04505774 STU00213958 |
Immune response to SARS-CoV-2 vaccination in sarcoidosisThe purpose of this study is to investigate the antibody and immune responses to the COVID-19 vaccine in patients with sarcoidosis, both treated and not treated with immunosuppressive medications, compared to healthy controls. This study will address a critical gap in our understanding of vaccine responses in people with … The purpose of this study is to investigate the antibody and immune responses to the COVID-19 vaccine in patients with sarcoidosis, both treated and not treated with immunosuppressive medications, compared to healthy controls. This study will address a critical gap in our understanding of vaccine responses in people with sarcoidosis. Participants will:
Sarcoidosis Patients
Controls
STU00215567 |
Longitudinal assessment of early immune response and SARS-CoV-2 infection using DASH rapid PCR during COVID-19Almost 100 million Americans have gotten COVID-19. If you recently tested positive, team up from the comfort of home and collect your own fluid samples (like nasal swabs, saliva and blood). Your participation might help lead to better testing methods!… Almost 100 million Americans have gotten COVID-19. If you recently tested positive, team up from the comfort of home and collect your own fluid samples (like nasal swabs, saliva and blood). Your participation might help lead to better testing methods! Inclusion: - 18 - Must have tested positive for Covid-19 or presumed positive due to significant exposure Addition screening question: Do you live within 2 miles of Northwestern Memorial Hospital Arkes Pavillion or the Northwestern Evanston campus? STU00216945 |